The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA).
 
E. Gabriela Chiorean
Consulting or Advisory Role - Axiom Healthcare Strategies; Bayer; BioNTech; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; Ipsen; Merck; Novartis; Noxxon Pharma; Noxxon Pharma; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); FibroGen (Inst); Halozyme (Inst); Lonza (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
 
Aude Chapuis
Research Funding - Affini-T Therapeutics; Lonza
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Nextrast (Inst); Novocure (Inst); Nucana (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme; Nucana
 
Cecilia CS Yeung
Consulting or Advisory Role - Loxo/Lilly; Merck; TwinStrand Biosciences
Research Funding - OBI Pharma; Pfizer
 
Ted Gooley
Consulting or Advisory Role - Kiadis Pharma; Pharmacyclics; Regimmune
 
David Bing Zhen
Consulting or Advisory Role - Cornerstone Pharmaceuticals; Ipsen; QED Therapeutics
Research Funding - AstraZeneca; Bristol Myers Squibb; Cornerstone Pharmaceuticals; Daiichi Sankyo/Astra Zeneca; Genentech; Legend Biotech; Lilly; Merck; Seagen; TME Pharma
 
Gentry Teng King
Consulting or Advisory Role - Novartis; Pfizer; QED Therapeutics; Tempus; Zymeworks
Research Funding - Bayer (Inst)
 
Lindsay Marie Hannan
No Relationships to Disclose
 
Stacey A. Cohen
Consulting or Advisory Role - Association of Community Cancer Centers (ACCC); Bayer; Istari oncology; Kallyope; Pfizer; Taiho Oncology
Research Funding - Boston Biomedical (Inst); EMD Serono/Merck (Inst); Isofol Medical (Inst); Natera; Pfizer (Inst); Polaris (Inst)
Expert Testimony - helsell Fetterman; Robins Kaplan
 
Rachael A Safyan
Research Funding - Merck (Inst)
 
Anthony Germani
No Relationships to Disclose
 
Susan Ra
No Relationships to Disclose
 
Jennifer Casserd
No Relationships to Disclose
 
Thomas Schmitt
Stock and Other Ownership Interests - Affini-T Therapeutics; SignalOne Bio
Consulting or Advisory Role - Affini-T Therapeutics; SignalOne Bio
Research Funding - Affini-T Therapeutics; Cullinan Oncology; Lonza; SignalOne Bio
Patents, Royalties, Other Intellectual Property - licensing distributions through my institution from IP licensed to affini-T Therapeutics; licensing distributions through my institution from IP licensed to Cullinan Oncology; licensing distributions through my institution from IP licensed to Lonza
 
Philip D Greenberg
Stock and Other Ownership Interests - Affini-T Therapeutics; Catalio; Celsius Therapeutics; Earli; Elpiscience; Fix Bio; ImmunoSCAPE; Juno Therapeutics; Metagenomi; Nextech Invest; RAPT Therapeutics
Consulting or Advisory Role - Affini-T Therapeutics; Catalio; Celsius Therapeutics; Earli; Elpiscience; FLX Bio; ImmunoSCAPE; Juno Therapeutics; Metagenomi; Nextech Invest; RAPT Therapeutics
Research Funding - Affini-T Therapeutics; Juno Therapeutics; Lonza
Patents, Royalties, Other Intellectual Property - Adaptive Biotechnologies; Affini-T Therapeutics; Juno Therapeutics has licensed technology on T cell therapy originating from my laboratory; Lonza
Travel, Accommodations, Expenses - Elpiscience; FLX Bio; Nextech Invest; RAPT Therapeutics